Key facts: Foundayo trial win; Jefferies hikes target; Hims pricing

What happened

Eli Lilly said Foundayo met the main goal in a Phase 3 sleep apnea trial, with patients losing about 11% of body weight after 52 weeks. Lilly plans to seek U.S. approval by the end of 2026. Separately, it and Hims & Hers will offer Foundayo and Zepbound to eligible patients at self-pay prices.

Confirmed

Global impact / market context

The trial result could support Lilly’s effort to expand Foundayo’s uses, but approval is still pending. The planned self-pay offers give eligible patients another way to buy Lilly’s drugs and could help generate sales directly, though the article gives no expected volume or revenue.

Analyst inference

The article also reports that Jefferies raised its Lilly price target to $1,700 from $1,610, citing overseas GLP-1 potential and Lilly’s drug portfolio. GLP-1 drugs are medicines that act on a hormone involved in appetite and blood sugar control; the target is an analyst estimate, not a guaranteed share price.

Confirmed

What to watch

1. Watch whether Lilly submits its planned U.S. approval application for Foundayo by the end of 2026; regulators’ decisions would determine whether the sleep apnea use can be sold. Analyst inference
2. Track whether the self-pay offers launch at the stated monthly prices: $299 for Zepbound and $149 for Foundayo, for eligible patients through Hims & Hers. Confirmed
3. Watch for evidence that the overseas GLP-1 opportunity and Lilly’s wider drug portfolio translate into sales growth; Jefferies cited these factors when raising its price target. Analyst inference

Evidence

• Original source link unavailable